Last updated: March 16, 2026
What is NDC 58151-0241?
NDC 58151-0241 corresponds to Fasenra (benralizumab), a monoclonal antibody developed by AstraZeneca. It is indicated for the treatment of severe eosinophilic asthma in adults and adolescents aged 12 and older. Launched in 2017, Fasenra is administered via subcutaneous injection every four weeks initially, then every eight weeks.
Market Overview
Market Size and Growth
The global severe eosinophilic asthma market is projected to grow at a CAGR of approximately 9% from 2022 to 2027, driven by increased diagnosis rates, expanding approval indications, and the uptake of biologic therapies. In 2022, the market was valued roughly at $4.3 billion; by 2027, it could reach $6.6 billion.
Key Competitors
- Nucala (mepolizumab): Lilly, approved since 2015.
- Cinqair (reslizumab): Teva, approved since 2016.
- Dupixent (dupilumab): Sanofi/Regeneron, approved for multiple eosinophilic conditions in 2018.
Adoption Trends
- Fasenra's use is concentrated among patients with high eosinophil counts.
- Prescriber preference favors agents with validated dosing flexibility.
- Insurance coverage favors agents with demonstrated cost-effectiveness and minimal adverse events.
Regulatory Landscape
- Approved by FDA in November 2017.
- Also approved in Europe and Japan.
- Ongoing trials expand indications to other eosinophilic diseases.
Pricing Mechanics
Current Pricing
- Average wholesale price (AWP): Approximately $35,000 per dose.
- Per dose: $34,775 - $36,600 depending on source.
- Monthly treatment cost: For initial dosing (four weeks), about $140,000; subsequent maintenance doses, approximately $69,000 every eight weeks.
Reimbursement and Market Factors
- Insurance reimbursements vary, with most payers favoring branded biologics for severe asthma.
- The high cost constrains broad adoption, though patient assistance programs mitigate patient out-of-pocket expenses.
Cost Comparison with Competitors
| Drug |
Typical Dose |
Approximate Cost per Dose |
Approved Indications |
| Fasenra |
30 mg subcutaneous |
$35,000 |
Severe eosinophilic asthma |
| Nucala |
100 mg subcutaneous |
$32,000 |
Eosinophilic conditions |
| Cinqair |
3 mg/kg intravenous |
$30,000 |
Severe eosinophilic asthma |
| Dupixent |
300 mg every two weeks |
$37,000 |
Multiple eosinophilic and allergic conditions |
Price Projections
Short-term (1–2 Years)
- Stable pricing: Marginal reductions likely driven by biosimilar development delays and regulatory considerations.
- Market pressures: Payers may negotiate discounts of 10–15% in some markets; manufacturer rebates could further reduce net prices.
Medium-term (3–5 Years)
- Potential decrease: Introduction of biosimilars or biobetters may lead to 20–30% price reductions.
- Market penetration: Increased competition could lower the average price per dose to approximately $25,000–$30,000.
Long-term (5+ Years)
- Pricing compression: Continued biosimilar entry and regulatory changes may push prices below current levels, potentially into the $20,000–$25,000 range.
- Innovation-driven pricing: New indications or combination therapies could sustain higher prices selectively.
Regulatory and Policy Influences
- FDA policies on biosimilar approval may impact pricing.
- Health system payers may implement formularies favoring lower-cost biologics.
- Market access strategies such as value-based pricing could influence future prices.
Summary
| Aspect |
Current Status |
Future Outlook |
| Price per dose |
~$35,000 |
Potential decrease to ~$25,000–$30,000 by 2025 |
| Market penetration |
Moderate, limited by high cost |
Expected increase with payer acceptance |
| Competition |
Competes with Nucala, Cinqair, Dupixent |
Biosimilar entry may impact prices |
| Pricing strategy |
Premium biologic, influenced by efficacy and convenience |
Shift towards value-based models |
Key Takeaways
- NDC 58151-0241 (Fasenra) commands a high per-dose price due to its biologic nature and target population.
- Market growth is driven by increasing asthma diagnosis, expanding indications, and competitive dynamics.
- Price reductions are anticipated with biosimilar development, but current trends favor sustained high prices in the near term.
- Reimbursement pressures, policy changes, and market access strategies significantly influence actual pricing.
- Competitive landscape and innovation will shape the long-term pricing trajectory for Fasenra.
FAQs
1. What factors influence Fasenra’s pricing?
Manufacturing costs, biologic complexity, approval status, payer negotiations, and competition affect Fasenra's pricing.
2. Are biosimilars likely to enter the Fasenra market soon?
Biosimilar development is ongoing, but delays in approval and market entry are common, with significant impact expected within 3–5 years.
3. How does Fasenra’s price compare to competitors?
It is comparable, with average doses around $35,000; slight variations depend on dosing and administration routes.
4. What is the expected trend in biologic pricing for asthma?
Prices are expected to decline gradually due to biosimilar competition and payer cost-containment measures.
5. How do regulatory policies impact future prices?
Enhanced biosimilar approval processes and pricing regulations can drive downward pressure on biologic prices.
References
[1] GlobalData. (2022). Forecast: Severe eosinophilic asthma market, 2022-2027.
[2] IQVIA. (2022). The Impact of Biologics on Asthma Therapy.
[3] U.S. Food and Drug Administration. (2017). Fasenra (benralizumab) approval.
[4] MarketWatch. (2023). Biologic therapies in respiratory diseases.
[5] Parsad, D. (2022). Biologics pricing and reimbursement in respiratory indications.
